Natus Medical, Inc. (BABY) Misses Q4 EPS by 1c, Offers Q1 and FY12 Outlook
Get Alerts BABY Hot Sheet
Price: $26.75 --0%
Financial Fact:
Income from operations: 15.24M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Financial Fact:
Income from operations: 15.24M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Join SI Premium – FREE
Natus Medical, Inc. (NASDAQ: BABY) reported Q4 EPS of $0.14, $0.01 worse than the analyst estimate of $0.15. Revenue for the quarter came in at $64.1 million versus the consensus estimate of $64.97 million.
Natus Medical, Inc. sees Q1 2012 EPS of $0.00-$0.07, versus the consensus of $0.07. Natus Medical, Inc. sees Q1 2012 revenue of $55-$60 million, versus the consensus of $60.2 million.
Natus Medical, Inc. sees FY2012 EPS of $0.57-$0.62, versus the consensus of $0.60. Natus Medical, Inc. sees FY2012 revenue of $256-$262 million, versus the consensus of $260.37 million.
For earnings history and earnings-related data on Natus Medical, Inc. (BABY) click here.
Natus Medical, Inc. sees Q1 2012 EPS of $0.00-$0.07, versus the consensus of $0.07. Natus Medical, Inc. sees Q1 2012 revenue of $55-$60 million, versus the consensus of $60.2 million.
Natus Medical, Inc. sees FY2012 EPS of $0.57-$0.62, versus the consensus of $0.60. Natus Medical, Inc. sees FY2012 revenue of $256-$262 million, versus the consensus of $260.37 million.
For earnings history and earnings-related data on Natus Medical, Inc. (BABY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs Downgrades Norsk Hydro SA (NHY:NO) (NHYDY) to Neutral
- Pfizer's 25-valent pneumococcal vaccine shows Phase 2 results
- Investing.com’s stocks of the week
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!





Tweet
Share